Sargon Enterprises, Inc. v. University of Southern California

215 Cal. App. 4th 1495, 156 Cal. Rptr. 3d 372, 2013 WL 1833016, 2013 Cal. App. LEXIS 352
CourtCalifornia Court of Appeal
DecidedMay 2, 2013
DocketB202789
StatusPublished
Cited by40 cases

This text of 215 Cal. App. 4th 1495 (Sargon Enterprises, Inc. v. University of Southern California) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sargon Enterprises, Inc. v. University of Southern California, 215 Cal. App. 4th 1495, 156 Cal. Rptr. 3d 372, 2013 WL 1833016, 2013 Cal. App. LEXIS 352 (Cal. Ct. App. 2013).

Opinion

*1499 Opinion

JOHNSON, J.

Sargon Enterprises, Inc. (Sargon), appeals judgment in its breach of contract action against the University of Southern California (USC) arising out of a clinical trial of Sargon’s dental implant under study at USC. In a previous appeal, this court reversed as an abuse of discretion the trial court’s eve-of-trial exclusion of the trial testimony on lost profit damages of Sargon’s principal expert witness, James Skorheim. The Supreme Court granted review and reversed, concluding the trial court acted within its discretion in excluding the evidence, and remanded the matter to this court for further proceedings.

On remand, Sargon submitted a supplemental brief 1 arguing that the Supreme Court announced a new rule of evidentiary procedure, and asking this court to remand the matter to the trial court for a new trial to permit Sargon to present lost profit damages in conformity with this new standard. USC has requested that we dismiss its cross-appeal. We affirm the judgment of the trial court, and dismiss USC’s cross-appeal.

FACTUAL BACKGROUND AND PROCEDURAL HISTORY

1. Procedural Summary

(a) Sargon’s First Appeal

In 1992, Sargon obtained patents on a dental implant that could be implanted immediately following extraction and contained both the implant and a full restoration. Sargon wanted USC to teach the implant at its dental school, and USC requested that a clinical study be conducted to allow USC to provide academic support for the device. 2 In November 1996, the parties entered into a clinical trial agreement (CTA), intending to conduct a five-year study of the implant. Over a year into the study, Sargon contended USC failed to timely deliver the promised reports and otherwise breached the CTA.

On May 7, 1999, Sargon initiated this action against USC and faculty members of USC’s dental school involved in the study. Sargon asserted claims for breach of contract, fraud, and other torts. USC cross-claimed for breach of contract. After Sargon’s tort claims and claims against the individuals were eliminated by demurrer and summary judgment, the remaining *1500 contract action against USC was tried in 2003. Before trial, the court ruled in limine and excluded evidence of Sargon’s lost profit damages on the grounds they were not foreseeable to defendants. The jury awarded Sargon $433,000 in compensatory damages on its breach of contract claim, and found for it on USC’s cross-complaint for breach of the CTA.

Sargon appealed the judgment and this court reversed, finding the trial court erred in excluding evidence of Sargon’s lost profits on the grounds of foreseeability and remanded for a new trial on that issue. This court also reversed the judgment of dismissal on Sargon’s fraud claims. (Sargon Enterprises, Inc. v. University of Southern California (Feb. 25, 2005, B167519) [nonpub. opn.] (Sargon I).)

(b) Exclusion of Sargon’s Expert on Remand

On remand, in April 2006, Sargon filed a second amended complaint based on two contract and four tort theories. Sargon’s breach of implied covenant claim was dismissed by demurrer, its tort claims by summary adjudication, and the case again proceeded to trial on the breach of contract claim for lost profits.

Trial commenced in July 2007. Sargon’s principal proof of lost profits was to be based upon the testimony of James Skorheim, who used a market-share hypothesis to compare Sargon to six multinational companies (Big Six) that were the dominant market leaders in the industry, with collectively in excess of 80 percent of global sales of dental implants. Sargon used three core factors to evaluate the basis of the six companies’ respective market shares: innovation, clinical studies, and outreach to general practice dentists. Skorheim concluded that Sargon had the same business metric of the Big Six, and its lost profits resulting from USC’s breach of the CTA ranged from $220 million to $1,181,000,000.

During Skorheim’s Evidence Code section 402 hearing, on July 17, 2007, Sargon also sought to introduce a theory of lost profits based on Sargon’s 1998 revenues (a year for which Sargon had concrete profit data), to which Skorheim would apply a growth rate based on industry projections. The trial court excluded this testimony, terming it a “sea change” in Skorheim’s opinion. On July 30, 2007, after the trial court announced its tentative ruling *1501 excluding Skorheim’s market-share-based expert opinion, Sargon advised the court that it would call Skorheim as a rebuttal witness to refute USC’s defense expert. Sargon advised the court that it would prepare a lost profits analysis based upon a “traditional, standard type of analysis configured to the market” that would “replicate and use the historical financial data in some substantial form” but that the opinion had not been precisely formulated. However, Sargon never put on such evidence.

The trial court issued a lengthy written decision excluding Sargon’s core theory of damages, Skorheim’s market-driver methodology, finding it to be too speculative. The court relied on Evidence Code sections 402 and 801, stating that “case law demands that to establish such lost profits through expert testimony, the expert must base his/her opinion on either historical performance of the company or a comparison to the profits of companies similar in size, locality, sales, products, number of employees, and other relevant financial factors. A party is not permitted to ‘make up’ its own factors as a basis for comparison and invite the jury to consider whether the corporations are similar.” The court summarized, “Mr. Skorheim’s opinions are not based upon matters upon which a reasonable expert would rely, and do not show the nature and occurrence of lost profits with evidence of reasonable reliability, because his opinion is not based on any historical data from Plaintiff or a comparison to similar businesses” and as a result, Skorheim’s opinion rested on speculation and unreasonable assumptions. As Sargon had not challenged the court’s ruling excluding its alternative theory of damages based on Sargon’s industry-projected growth rate, or attempted to put on damages based on a rebuttal challenge to USC’s own expert, the court did not address lost profits calculated on such bases.

In August 2007, the parties stipulated to entry of judgment for $433,000 in compensatory damages on the breach of contract claim to permit Sargon to seek appellate review of the in limine motion excluding lost profits.

On February 9, 2011, this court reversed the trial court’s exclusion of Skorheim’s expert testimony on market-driver-based lost profit damages, and affirmed dismissal of Sargon’s breach of the implied covenant claim and its tort claims. In its appellate briefs, Sargon did not advance any claim of trial court error with respect to its alternative theories of lost profits. At oral argument in Sargon II, the issue arose in response to a question from this court. (Sargon Enterprises, Inc. v. University of Southern California (Feb.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Radovic v. Milosevic CA4/1
California Court of Appeal, 2026
Asi v. Hollywood Foreign Press Assn. CA2/4
California Court of Appeal, 2026
Paknad v. Super. Ct.
California Court of Appeal, 2026
Paknad v. Superior Court CA6
California Court of Appeal, 2026
Soleimany v. Narimanzadeh CA2/4
California Court of Appeal, 2026
Milder v. Holley CA2/5
California Court of Appeal, 2026
Cerda v. City of Los Angeles CA2/3
California Court of Appeal, 2024
Canyon View Limited v. Bank of America CA2/1
California Court of Appeal, 2023
Marriage of Blum and Herbstman CA6
California Court of Appeal, 2023
People v. Flitcroft CA1/5
California Court of Appeal, 2022
People v. Polk CA4/2
California Court of Appeal, 2022
BMO Harris Bank N.A. v. Hassanally CA1/1
California Court of Appeal, 2022
Caron v. Cal. State Board of Pharmacy CA4/1
California Court of Appeal, 2022
Karamooz v. Karamooz CA4/3
California Court of Appeal, 2022
Darquea v. Baev CA1/3
California Court of Appeal, 2022
Dept. of Forestry & Fire Protection CA3
California Court of Appeal, 2022
Meza v. Pacific Bell Telephone Co.
California Court of Appeal, 2022
People v. McDavid
California Court of Appeal, 2022

Cite This Page — Counsel Stack

Bluebook (online)
215 Cal. App. 4th 1495, 156 Cal. Rptr. 3d 372, 2013 WL 1833016, 2013 Cal. App. LEXIS 352, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sargon-enterprises-inc-v-university-of-southern-california-calctapp-2013.